scispace - formally typeset
P

Piotr Ruchala

Researcher at University of California, Los Angeles

Publications -  66
Citations -  3288

Piotr Ruchala is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Hepcidin & Peptide. The author has an hindex of 27, co-authored 65 publications receiving 2837 citations. Previous affiliations of Piotr Ruchala include University of California & Semel Institute for Neuroscience and Human Behavior.

Papers
More filters
Journal ArticleDOI

Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload

TL;DR: Modifications to increase resistance to proteolysis and oral bioavailability yielded minihepcidins that, after parenteral or oral administration to mice, lowered serum iron levels comparably to those after paretteral native hepcidin, which may be useful for the treatment of iron overload disorders.
Journal ArticleDOI

Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.

TL;DR: It is demonstrated that minihepcidins could be beneficial in iron overload disorders either used alone for prevention or possibly as adjunctive therapy with phlebotomy or chelation.
Journal ArticleDOI

Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I

TL;DR: The results indicate that specific mimetic peptides have an increased binding affinity for oxidized phospholipids, compared with the parent nonoxidized phosphoattractant protein-1 (MCP-1) whereas full-length human apoA-I binds oxidized and nonoxids phospholIPids similarly.
Journal ArticleDOI

Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus

TL;DR: It is demonstrated that hepcidin-mediated hypoferremia is a host defense mechanism against siderophilic pathogens and suggested that hePCidin agonists may improve infection outcomes in patients with hereditary hemochromatosis or thalassemia.